- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 12: A New Precedent for Healthcare
The situation with hepatitis C drug costs is setting an interesting precedent for the rest of healthcare and one that needs to be watched closely, according to Keith Hoffman, PhD.
The situation with hepatitis C drug costs is setting an interesting precedent for the rest of healthcare and one that needs to be watched closely, according to Keith Hoffman, PhD.
Matthew D. Harman, PharmD, MPH, added that the upcoming PCSK9 for high cholesterol is highlighting the trend of the “specialization of traditional drug classes.” For instance, there are medications coming out for asthma and diabetes that are more targeted.
“[These targeted therapies] are going to cost tens of thousands of dollars and there’s most likely will be demand for that,” he said. “And how are we going to sustain that?”
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Opportunities and Obstacles Associated With the Medicare Diabetes Prevention Program
October 3rd 2025This study describes the current opportunities and obstacles associated with Medicare Diabetes Prevention Program implementation from the novel perspective of program suppliers across the US.
Read More
